Apolipoprotein mRNA (Apo mRNA)

Apolipoprotein mRNA refers to the messenger RNA transcripts encoding various apolipoproteins, which are essential protein components of lipoproteins like LDL, VLDL, and HDL. These mRNAs have become prominent therapeutic targets for RNA-based drugs, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), designed to treat dyslipidemias and reduce cardiovascular risk (PMID: 23913122). Key targets within this class include Apolipoprotein B (ApoB) mRNA, targeted by mipomersen to lower LDL-C in familial hypercholesterolemia, and Apolipoprotein C-III (ApoC3) mRNA, targeted by agents like volanesorsen and olezarsen to manage severe hypertriglyceridemia (PMID: 38461234). Additionally, Apolipoprotein(a) mRNA is targeted by drugs like pelacarsen and olpasiran to reduce Lipoprotein(a) levels, an independent risk factor for atherosclerosis. These therapies typically work by inducing sequence-specific degradation of the target mRNA in hepatocytes, often facilitated by GalNAc conjugation for liver-specific delivery. The use of mRNA-targeting strategies allows for the modulation of lipid pathways that were previously considered undruggable by traditional small molecules.

Other names

Apolipoprotein messenger RNAApolipoprotein B mRNAApolipoprotein C-III mRNAApolipoprotein(a) mRNALPA mRNAAPOC3 mRNAAPOB mRNA

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target specific apolipoprotein mRNA sequences to induce RNase H-mediated degradation or RISC-mediated silencing, thereby reducing the translation of the corresponding apolipoprotein proteins (PMID: 23913122, 38461234).